Study to Reinforce Immunity (STRI) Phase 2 Clinical Trial

  • End date
    Aug 20, 2023
  • participants needed
  • sponsor
    Eyecheck, Inc.
Updated on 7 October 2022


Protocol STRI12 - Study to Reinforce Immunity (STRI) - A Phase 2 Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of STRI Formula in Non-Hospitalized Participants with COVID-19 (the Study)


The Study to Reinforce Immunity (STRI) Phase 2 Clinical Trial is a randomized, double-blind, placebo-controlled clinical trial protocol assessing the safety and efficacy of STRI Formula in non-hospitalized participants with COVID-19. STRI Formula is a combination of food-based substances designed specifically to combat SARS-CoV-2, the coronavirus that causes COVID-19.

The primary objective of the Study is to assess the efficacy of STRI Formula in reduction of time from treatment initiation to initial meaningful clinical improvement in COVID-19 symptoms. Additional secondary objectives are as follows:

  1. To assess the safety of STRI Formula
  2. To assess the efficacy of STRI Formula in reduction of time to COVID-19 sustained symptom improvement
  3. To assess the efficacy of STRI Formula in reduction of time to COVID-19 initial symptom resolution
  4. To assess the efficacy of STRI Formula in reduction of time to COVID-19 sustained symptom resolution
  5. To assess the efficacy of STRI Formula in reduction in need for hospitalization
  6. To assess the efficacy of STRI Formula in reduction in rates of fever
  7. To assess the efficacy of STRI Formula in reduction in rates of hypoxia

Condition Covid19
Treatment Placebo, STRI Formula
Clinical Study IdentifierNCT05046561
SponsorEyecheck, Inc.
Last Modified on7 October 2022


Yes No Not Sure

Inclusion Criteria

Adults residing in the United States aged 18 years or older
Provision of documentation of positive SARS-CoV-2 testing (via RT-PCR, rapid antigen testing) performed less than 7 days before screening, either via direct upload or confirmation from PCP
electronic secure document upload
allowing STRI Personnel to contact the PCP to confirm diagnosis; or
allowing STRI Personnel to contact the laboratory where the RT-PCR analysis was performed
Initial date of onset of COVID-19 signs/symptoms 7 days or less from date of STRI
During screening (Day 0)
Screening and Randomization (i.e., Day 0)
participant-reported response of "Mild" or "Moderate" in response to the question "Overall, how severe were your infection symptoms today?" (FLU-PRO Plus Global Additional Daily Diary Items Question 1)
During prescreening, participant self-reported response of "A little worse" or "Somewhat worse" or "Much worse" or "About the same" in response to the question "Overall, how were your infection symptoms today compared to yesterday?" (FLU-PRO Plus Global Additional Daily Diary Items Question 2)
During prescreening, participant-reported response of "No" in response to the question "Have you returned to your usual health today?" (FLU-PRO Plus Global Additional Daily Diary Items Question 6)
At least TWO participant self-reported responses of "Somewhat," "Quite A Bit," or "Very Much" in any FLU-PRO Plus domain other than smell and taste (i.e., nose, throat, eyes, chest/respiratory, head, gastrointestinal, or body/systemic domains)
Provision of signed and dated electronic informed consent form (via 21 CFR Part 11 compliant platform)
Ability to self-measure and self-report body temperature, and peripheral oxygen
saturation (with STRI provided thermometer and STRI provided pulse oximeter)
Provision of participant's primary care physician (PCP) name and phone number
Consent to allow STRI Personnel to contact PCP for any reason and discuss participant's medical history and/or obtain participant's medical records
Stated willingness to comply with all study procedures and availability for the duration of the study, including intent to comply with lifestyle considerations throughout Study duration
Ability to take oral medication and be willing to adhere to the STRI Intervention Product (STRI Formula or placebo as capsules) regimen
Ability to use the internet daily and check email daily
Ability and consent to send and receive SMS text messages via cellular phone
Provision of information (name, email address, and cellular phone number) of an emergency contact (e.g., family member/friend/colleague) willing to communicate with STRI Personnel in case the participant deteriorates
Willingness to discontinue any dietary supplement that contains any active ingredient in STRI Formula (ascorbic acid, cholecalciferol, zinc, copper, quercetin, hesperidin, caffeic acid, epigallocatechin gallate, bovine lactoferrin) for the duration of the Study
For men and women with child-bearing potential (as defined below), willingness to use adequate contraception for at least 100 days after beginning the Study

Exclusion Criteria

Inability to comply with study or follow-up procedures, or provide regular updates to their health status when contacted by the STRI Personnel via email, SMS, or phone
Any prior or current hospitalization for COVID-19 or any need for hospitalization for any reason
Any prior or current treatment with any agent for COVID-19
Any known allergies or known toxicities to any of the specific ingredients in STRI Formula (including ascorbic acid, vitamin D, zinc, copper, amla, caffeic acid, coffee, bovine lactoferrin, milk, quercetin, hesperidin, oranges, citrus fruits, and/or green tea)
Body Mass Index > 40 based on participant-reported weight and participant-reported height
Participant-reported weight of less than 35kg
Any history of radiation or chemotherapy for cancer within the last 3 months
Any history of cardiac arrythmias, hemochromatosis, renal (including any known GFR < 60mL/min) or hepatic disease (including chronic liver disease)
Any history of chronic pulmonary disorders
Any history of any gastrointestinal surgery or disease (including bariatric surgery or gastrointestinal resection, inflammatory bowel disease, or chronic intestinal diseases, such as (but not limited to) eosinophilic enteritis or autoimmune enteritis)
Any history of mineral or vitamin overload or deficiency (including chronic iron overload states, copper overload states, or ascorbic acid, vitamin D, zinc, or copper deficiencies)
Any history of any adverse event to green tea extract or any herbal products
Prescreening Alcohol Use Disorders Identification Test (AUDIT) score of 8 or more indicating hazardous or harmful alcohol consumption, or alcohol dependence
Pregnant or nursing/breastfeeding participants or participants intending to become pregnant within the next 24 months
Men or premenopausal women not using adequate contraception
Any other factors as judged by the principal investigator that would cause harm or increased risk to the participant or preclude the participant's full adherence with or completion of the study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note